Janssens Rosanne, Arnou Reinhard, Schoefs Elise, Petrocchi Serena, Cincidda Clizia, Ongaro Giulia, Oliveri Serena, Smith Meredith Y, Louis Evelyne, Vandevelde Marie, Nackaerts Kristiaan, Pravettoni Gabriella, Huys Isabelle
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Front Pharmacol. 2021 Sep 23;12:710518. doi: 10.3389/fphar.2021.710518. eCollection 2021.
The lung cancer (LC) treatment landscape has drastically expanded with the arrival of immunotherapy and targeted therapy. This new variety of treatment options, each with its own characteristics, raises uncertainty regarding the key aspects affecting patients' health-related quality of life (HRQL). The present qualitative study aimed to investigate how LC patients perceive their HRQL and the factors that they consider to be most influential in determining their HRQL. This qualitative research incorporates four focus group discussions, with six LC patients in each group. In total, 24 stage III and IV LC patients were included in the discussions, with Italian ( = 12) and Belgian ( = 12) patients, age range: 42-78, median age = 62 (IQR = 9.3 years), SD = 8.5; 62% men. Using thematic analysis, transcripts and notes from the FGDs were analyzed using NVivo software (edition 12). Three main themes capturing determinants of HRQL were identified. First, patients agreed on the importance of physical aspects (symptoms and side-effects) in determining their HRQL. In particular, skin conditions, nausea, fatigue, risk of infections, sensory abnormalities, pain, and changes in physical appearance were highlighted. Second, patients worried about psychological aspects, negatively impacting their wellbeing such as uncertainties regarding their future health state, and a lower degree of autonomy and independence. Third, patients underlined the importance of social aspects, such as communication with healthcare providers and social interaction with friends, family and peers. This study demonstrates that physical, psychological, and social aspects are key factors driving LC patients' HRQL. Gaining a better understanding of how LC patients perceive their HRQL and how it is affected by their illness and therapy will aid patient-centric decision-making across the drug life cycle, by providing stakeholders (drug developers, regulators, reimbursement bodies, and clinicians) insights about the treatment and disease aspects of importance to LC patients as well as the unmet needs LC patients may have regarding available treatment modalities. Finally, this study underscores a need for individual treatment decision-making that is considerate of uncertainties among LC patients about their future health state, and ways for improving communication between healthcare providers and patients to do so.
随着免疫疗法和靶向疗法的出现,肺癌(LC)的治疗格局已大幅扩展。这种新的多种治疗选择,每种都有其自身特点,引发了关于影响患者健康相关生活质量(HRQL)的关键方面的不确定性。本定性研究旨在调查肺癌患者如何看待他们的HRQL以及他们认为在决定其HRQL方面最具影响力的因素。 这项定性研究纳入了四次焦点小组讨论,每组有六名肺癌患者。讨论总共纳入了24名III期和IV期肺癌患者,其中意大利患者(n = 12)和比利时患者(n = 12),年龄范围:42 - 78岁,中位年龄 = 62岁(四分位间距 = 9.3岁),标准差 = 8.5;62%为男性。使用主题分析法,通过NVivo软件(第12版)对焦点小组讨论的文字记录和笔记进行分析。确定了三个捕捉HRQL决定因素的主要主题。首先,患者一致认为身体方面(症状和副作用)在决定其HRQL方面很重要。特别是,皮肤状况、恶心、疲劳、感染风险、感觉异常、疼痛和外貌变化被突出强调。其次,患者担心心理方面会对其幸福感产生负面影响,例如对未来健康状况的不确定性,以及自主性和独立性降低。第三,患者强调了社会方面的重要性,例如与医疗服务提供者的沟通以及与朋友、家人和同龄人之间的社交互动。 本研究表明,身体、心理和社会方面是驱动肺癌患者HRQL的关键因素。更好地了解肺癌患者如何看待他们的HRQL以及它如何受到疾病和治疗的影响,将有助于在药物生命周期中以患者为中心进行决策,为利益相关者(药物开发者、监管机构、报销机构和临床医生)提供关于对肺癌患者重要的治疗和疾病方面的见解,以及肺癌患者在可用治疗方式方面可能存在的未满足需求。最后,本研究强调需要进行个性化治疗决策,要考虑到肺癌患者对其未来健康状况的不确定性,以及改善医疗服务提供者与患者之间沟通的方法。